10 results about "Complications treatment" patented technology

The invention discloses allicin oleogel as well as a preparation method and application thereof, and belongs to the technical field of medicines. The allicin oleogel is prepared from the following raw materials: allicin, an oil phase, a gelator and a surfactant, the gelator comprises beeswax and / or fruit wax; the surfactant comprises one or more of caprylic / capric polyethylene glycol glyceride, Tween 20 and polyglycerol fatty acid ester. The gel factor forms oil gel through crystal self-assembly, allicin is solidified and intercepted in the oil gel, the gel factor is optimized, and a surfactant is used in a matched manner, so that a release behavior similar to that of a mixed solution of free allicin and an oil phase can be obtained, and the transdermal release rate is improved. The allicin oil gel can effectively entrap allicin, cover the peculiar smell of the allicin and improve the stability of the allicin, and through abdominal transdermal administration, the medicine accumulation amount in subcutaneous adipose tissues is remarkably increased, and the treatment effect on obesity and complications thereof can be improved.

The invention belongs to the technical field of medicines, and discloses an application of a small molecule compound in preparation of a product for preventing and / or treating pulmonary arterial hypertension and complications thereof. The small molecule compound is 8-[[4-(cyclopropanecarbonyl) piperazine-1-yl] methyl]-1, 3-dimethyl-7-(3-methylbutyl) purine-2, 6-diketone, and the structural formula is as shown in a formula (I): # imgabs0. The small molecule compound and pharmaceutically acceptable salts thereof have a remarkable treatment effect on pulmonary arterial hypertension and complications thereof, and can be used for treating pulmonary arterial hypertension and complications thereof. The effects of preventing and / or treating the pulmonary arterial hypertension include the reduction of right heart hypertrophy, the reduction of right ventricular systolic pressure, right heart enlargement, right heart dysfunction, pulmonary vascular remodeling, pulmonary arterial intima thickness, increase of vascular myelization, pulmonary arterial smooth muscle cell proliferation and migration, the reduction of the right ventricular hypertrophy, the reduction of the right ventricular hypertrophy, the reduction of the right ventricular hypertrophy and the reduction of the right ventricular hypertrophy. The pulmonary arterial intima thickness and the vascular myelization level are improved, pulmonary vascular remodeling is reversed, and pulmonary artery smooth muscle cell proliferation and migration are inhibited.

The invention belongs to the technical field of medicines, and discloses application of WZ3146 in preparation of products for preventing and / or treating pulmonary arterial hypertension and complications thereof. The WZ3146 and the pharmaceutically acceptable salt thereof have a remarkable treatment effect on pulmonary arterial hypertension and complications thereof, such as mean pulmonary arterial pressure, high right ventricular systolic pressure, right heart enlargement, right heart dysfunction, pulmonary vascular remodeling, pulmonary arterial intima thickness, increase of vascular myelization, pulmonary artery smooth muscle cell proliferation and migration and the like; the effects of preventing and / or treating pulmonary arterial hypertension comprise expanding the right heart, improving the pulmonary arterial intima thickness and the vascular myelization level, reversing pulmonary vascular remodeling and inhibiting pulmonary artery smooth muscle cell proliferation and migration.

This invention discloses a meglumine-luteolin complex, its preparation method, and its applications, belonging to the interdisciplinary field of microbiome and drug delivery. Using luteolin as the main material, this invention employs a dual inclusion technique with hydroxypropyl-β-cyclodextrin and meglumine to synergistically prepare a meglumine-luteolin complex with colon-targeted delivery capabilities. This invention significantly improves the delivery efficiency and drug loading of luteolin in the colon through the dual inclusion technique. The preparation process is simple, and it exhibits excellent hypoglycemic effects and colon-targeted release characteristics in the treatment of diabetes and its complications.

The application belongs to the technical field of medicine, and discloses the use of a composition targeting the intestinal flora-UCP1 axis in preventing and / or treating metabolic syndrome and complications thereof. Specifically, the application relates to the use of tea extract, panax notoginseng extract and dendrobium extract in combination as active ingredients in the treatment of metabolic syndrome and complications thereof, and the use of any two or more of tea extract, panax notoginseng extract and dendrobium extract as active ingredients in combination with other active ingredients and excipients in the preparation of a compound drug preparation for clinical use in a daily dosage of 0.001-2000 mg / kg body weight. The application has a synergistic effect, is used for treating metabolic syndrome and complications thereof, reduces the dosage of a single agent, improves the prevention and treatment effect, reduces side effects, lowers the cost, and meets the basic requirements of health economics.

The invention relates to the technical field of surgical operation training, and particularly discloses a training method and system for an anterior-lateral free flap operation based on mixed reality. The method comprises the steps that by obtaining a preoperative image and a body surface grid, tissue layering labeling and individualized deformable registration are carried out, and projection stability parameters are generated; carrying out perforation discovery and ultrasonic fusion projection, carrying out layered approach planning, and generating instrument navigation information; and then microscopic anastomosis visual touch closed-loop training and complication treatment evaluation are realized, and finally a trainee ability portrait is generated and a self-adaptive course engine is driven. According to the invention, through multi-modal data fusion and real-time feedback, high-fidelity simulation and personalized training of key operation steps are realized, and the training precision and efficiency are effectively improved.

The invention discloses application of microRNA-31-5P in preparation of drugs for treating metabolic liver diseases and complications thereof, and belongs to the technical field of biological medicines. A metabolic liver disease model is treated by adopting the extracellular vesicle microRNA-31-5P, it is innovatively found that the extracellular vesicle microRNA-31-5P can remarkably inhibit liver injury and effectively improve neurovascular complications, and the treatment effect and potential of the microRNA-31-5P in the metabolic liver disease and the complications of the metabolic liver disease are proved. The invention has important clinical application value and wide development prospect.

The invention discloses application of a specific liver targeting nucleic acid molecule in preparation of a medicine for treating obesity and complications thereof, and belongs to the technical field of biomedicine. The nucleic acid molecule is GalNAc-PRKAR1ASIRNA, the GalNAc-PRKAR1ASIRNA is obtained after the 3'tail end of PRKAR1ASIRNA is subjected to GalNAc coupling modification, and the base sequence of the PRKAR1ASIRNA is shown in the figure 1 in the specification. In-vivo experiments prove that the GalNAc-PRKAR1ASIRNA has a positive treatment effect on obesity and complications thereof, specifically, the GalNAc-PRKAR1ASIRNA obviously improves obesity induced by high fat diet, reduces the content of serum triglyceride, total cholesterol and blood sugar, reduces the content of liver fat, improves the athletic ability of mice, and has a remarkable treatment effect on obesity and complications thereof, so that the GalNAc-PRKAR1ASIRNA has a remarkable treatment effect on obesity and complications thereof, and the GalNAc-PRKAR1ASIRNA has a remarkable treatment effect on obesity and complications thereof. And candidate drugs are provided for treatment of obesity and complications thereof. And the GalNAc-PRKAR1ASIRNA specifically targets the liver tissue, so that compared with the existing obesity and complication treatment medicines, the GalNAc-PRKAR1ASIRNA has the advantages of smaller toxic and side effects and obvious curative effect, and makes obvious progress compared with the prior art.

The application discloses a cardiovascular disease home rehabilitation nursing method and system, and belongs to the technical field of intelligent medical treatment. The method synchronously collects physiological data, action postures, voice emotions, electronic medical records and other multi-type and multi-modal data of patients and completes preprocessing; a multi-modal cognitive knowledge graph covering disease types, nursing operations, drug management, complication treatment and patient dynamic state entities is built; a structure causal model is built relying on the knowledge graph, an optimal nursing scheme is screened through causal reasoning and counterfactual simulation, a recommended nursing path is output, rehabilitation nursing interaction is completed by a virtual nurse, patient interaction data is collected, local model incremental training is carried out, gradients are encrypted and then uploaded to a server for safe aggregation, a globally optimized model is iteratively generated, and an update is issued, so that nursing recommendation model co-evolution is realized. The application combines multi-modal cognitive graphs and causal reasoning, accurately matches home rehabilitation needs of cardiovascular patients, combines federal encryption training to guarantee data privacy, continuously optimizes nursing recommendation strategies, and improves the intelligence, individualization and safety of home rehabilitation nursing.

The invention belongs to the technical field of medicines and disease treatment, and particularly relates to application of polyamine in preparation of a product for treating radiation-induced oral mucositis. The polyamine comprises any one or more of spermine, spermidine and putrescine. The invention finds that the oral basal cell death mode caused after radiation exposure is mainly ferroptosis, the polyamine synthetase ODC1 is activated in the early stage of radiation, the polyamine production is increased, and the polyamine aggregates in the nucleus to inhibit the activation of JUND transcription factors, thereby inhibiting the SAT1-ACSL4 ferroptosis pathway. Research results show that after radiation, polyamine is used as an important medium to inhibit ferroptosis of basal cells and support renewal of mucosal epithelium. The inhibition effect of polyamine on ferroptosis provides a potential strategy for clinical treatment of radiation-related complications.